资源描述：
《Eph A5在卵巢癌组织中的表达及与临床特征和预后的关系》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。
1、EphA5在卵巢癌组织中的表达及与临床特征和预后的关系桑娜林春华陈旻唐蜜湖南省妇幼保健院病理科X关注成功！加关注后您将方便地在我的关注中得到本文献的被引频次变化的通知！·新浪微博·腾讯微博·人人网·开心网·豆瓣网·网易微博摘 要：目的探讨浆液性卵巢癌组织中酪氨酸蛋白激酶A5受体(EphA5)的表达水平变化、与患者临床病理学特征及预后的关系。方法浆液性卵巢癌病理组织标本94例作为恶性组、选取同期收集的卵巢浆液性囊腺瘤组织标本30例作为良性组,采用免疫组化染色观察2组标本中EphA5蛋白表达差异,并采用Logistic回归分析浆液性卵巢癌患者的预后影
2、响因素。结果恶性组的EphA5蛋白阳性表达率高于良性组(P<0.05);浆液性卵巢癌组织中EphA5蛋白表达与肿瘤分化程度、FIGO分期、淋巴结转移具有相关性(P<0.05);EphA5蛋白阳性表达的浆液性卵巢癌患者3年生存率高于阴性表达患者(P<0.05);EphA5蛋白阳性表达对浆液性卵巢癌患者远期预后有利(OR=0.629,P<0.05),低分化、FIGO分期增高、淋巴结转移时患者远期预后的不良因素(OR=1.833,OR=1.467,OR=1.625,P<0.05)。结论浆液性卵巢癌组织中EphA5蛋白的表达水平上调,与患者的肿瘤分化程度、FI
3、GO分期、淋巴结转移具有相关性,是患者远期预后的保护因素。关键词：浆液性卵巢癌;酪氨酸蛋白激酶A5受体;病理学特;预后;ExpressionofEphA5inovariancarcinomaanditsrelationshipwithclinicalfeaturesandprognosisofpatientsSANGNaLINChunhuaCHENMinDepartmentofPathology,HospitalforMaternalandChildHealthofHunanProvince;Abstract：ObjectiveToinvestigat
4、etheexpressionoftyrosinekinaseA5receptor(EphA5)inserousovariancancertissuesanditsrelationshipwithclinicopathologicalfeaturesandprognosisofpatients.MethodsNinety-fourcasesofserousovariancancertissuescollectedinourhospitalfromJanuary2010toDecember2013wereenrolledasmalignantgroup,m
5、eanwhile,30casesofovarianserouscystadenomatissueswereservedasbenigngroup.TheexpressionlevelsofEphA5proteinweredetectedbyimmunohistochemicalstainingforbothgroups,moreovertheinfluencingfactorsonprognosisofpatientswithserousovariancancerwereanalyzedbyLogisticregressionanalysis.Resu
6、ltsThepositiveexpressionrateofEphA5proteininmalignantgroupwas74.47%,whichwassignificatlyhigherthanthat(6.67%)inbenigngroup(P<0.05),moreover,theexpressionlevelsofEphA5proteininserousovariancancertissueswerecloselycorrelatedtotumordifferentiationdegree,FIGOstageandlymphnodemetasta
7、sis(P<0.05).The3-yearsurvivalrateinpatientswithpositiveexpressionofEphA5proteinwas65.71%,whichwassignificantlyhigherthanthat(41.67%)inpatientswithnegativeexpressionofEphA5proteinP<0.05).ThepositiveexpressionofEphA5proteinwasbeneficialforthelong-termprognosisofpatientswithserouso
8、variancancer(OR=0.629,P<0.05),however,lowerdiff
